Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond 9 to 12 months of ADT. HealthDay News — Increasing duration of androgen deprivation therapy (ADT) ...

An analysis of four randomized controlled studies in patients with advanced prostate cancer who had received early vs. deferred ADT as primary therapy showed that early androgen suppression ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

April 30, 2009 — Androgen-deprivation therapy (ADT) is a common treatment for men with prostate cancer, but patients who do undergo this therapy are at an increased risk for skeletal fracture, ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Most prostate cancers become castration-resistant in about two to ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, ...